Open AccessTolperisone in the treatment of acute and chronic nonspecific back pain
Author(s) -
В. А. Головачева,
А. А. Головачева,
O. E. Zinovyeva,
В Л Голубев
Publication year - 2020
Publication title -
nevrologiâ, nejropsihiatriâ, psihosomatika
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.157
H-Index - 9
eISSN - 2310-1342
pISSN - 2074-2711
DOI - 10.14412/2074-2711-2020-4-137-142
Subject(s) - medicine , muscle relaxant , muscle spasm , chronic pain , clinical trial , nonsteroidal , back pain , anesthesia , physical therapy , alternative medicine , pathology
Nonspecific back pain (NBP) is one of the most common reasons to see a neurologist or therapist. Acute ( 12 weeks) NBPs are recognized. The diagnosis of NBP is based on anamnestic data, somatic, neurological, and neurologic-and-orthopedic examination findings and on the exclusion of the specific causes of back pain, discogenic radiculopathy, and vertebral canal stenosis. Nonsteroidal anti-inflammatory drugs (NSAIDs) and muscle relaxants are used in the pharmacotherapy of acute, subacute, and chronic NBP. Tolperisone is widely used as a muscle relaxant in Russia and in the countries of Europe and Asia. Clinical trials have shown the efficacy and good tolerance of tolperisone used alone and in combination with NSAIDs for NBP. The review presents clinical recommendations from different countries on the use of muscle relaxants in the treatment of acute and chronic NBP. It is concluded that a large-scale qualitative randomized trial should be conducted to investigate the efficacy of muscle relaxants, tolperisone in particular, in the treatment of acute, subacute, and chronic NBP.